Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Home
/
update
/
details

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

NextEdge Admin

18 Nov 2024

2 min 51 sec

cancer screening,Carlos Ponce,Colorectal cancer,Hispanic adults

Exact Sciences, a leader in cancer screening, has partnered with award-winning Hispanic actor and philanthropist Carlos Ponce to promote awareness about colorectal cancer and the importance of early screening in the Hispanic community. This partnership includes a Spanish-language advertising campaign, personal stories, and educational resources in English and Spanish to help address health disparities.

Colorectal cancer is treatable in about 90% of cases when detected early, but screening rates among Hispanic adults remain low. Only 49% of eligible adults aged 45+ follow recommended screening guidelines, and the rates are even lower among those aged 45-49. Additionally, the Hispanic community has a higher percentage of colorectal cancer cases in individuals under 50 compared to non-Hispanic whites.

Ponce, a passionate advocate for health awareness, highlights the cultural challenges that often prevent open discussions about health in Hispanic families. “As Latinos, we often avoid health topics to appear strong or avoid worrying our families,” said Ponce. “But knowledge is power, and understanding testing options like colon cancer screening helps us ensure we’re present for our loved ones.”

Exact Sciences’ Cologuard® test offers a safe, effective, and non-invasive at-home screening option with no special preparation required. Dr. Xavier Llor, a gastroenterologist at Yale Medicine, stresses the importance of early detection, recommending screenings start at age 45 for those at average risk.

“Our partnership with Carlos Ponce reflects our commitment to improving colon cancer screening rates in underserved communities,” said Jeremy Truxal, VP of Marketing at Exact Sciences. By promoting awareness and providing Spanish-language resources, this initiative aims to increase screening rates and improve survival outcomes in the Hispanic community. Adults 45+ at average risk are encouraged to ask their doctors if Cologuard is right for them.